TY - CHAP M1 - Book, Section TI - Appendix III: Critical Values of X2 Required to Reject the Null Hypothesis A1 - Waning, Brenda A1 - Montagne, Michael PY - 2001 T2 - Pharmacoepidemiology: Principles and Practice AB - |Printdf0.050.010.00113.846.6410.8325.999.2113.8237.8211.3416.2749.4913.2818.46511.0715.0920.52612.5916.8122.46714.0718.4824.32815.5120.0926.12916.9221.6727.881018.3123.2129.591119.6824.7231.261221.0326.2232.911322.3627.6934.531423.6829.1436.121525.0030.5837.701626.332.0039.291727.5933.4140.751828.8734.8042.311930.1436.1943.822031.4137.5745.322132.6738.9346.802233.9240.2948.272335.1741.6449.732436.4242.9851.182537.6544.3152.622638.8845.6454.052740.1146.9655.482841.3448.2856.892942.5649.5958.303043.7750.8959.70 SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=2642353 ER -